VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age70+
SponsorNavy General Hospital, Beijing
About this trial
The goal of this phase 1/2 trial is to test the safety and efficacy of Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT in treating patients with higher-risk MDS.
Eligibility criteria
Qualifiers
The patient should, in the investigator's opinion, be able to meet all clinical trial requirements.
The patient is willing and able to adhere to the study visit schedule and other protocol requirements.
The patient should be diagnosed with higher risk MDS according to the standard criteria of the World Health Organization (WHO).
Disqualifiers
Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment.
Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy.
Trial design
Treatments tested in this trial
- Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT
Treatment groups
54 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov